- Home
- NUW vs LRMR Comparison
NUW vs LRMR Comparison
Compare NUW & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NUW | LRMR |
|---|---|---|
| Founded | 2008 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 256.9M | 260.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NUW | LRMR |
|---|---|---|
| Price | $14.48 | $3.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $16.71 |
| AVG Volume (30 Days) | 45.3K | ★ 1.2M |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | ★ 3.66% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.45 | $1.61 |
| 52 Week High | $14.44 | $5.37 |
Technical Indicators
Market Signals| Indicator | NUW | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 61.11 | 56.32 |
| Support Level | $14.23 | $3.05 |
| Resistance Level | $14.55 | $3.72 |
| Average True Range (ATR) | 0.11 | 0.23 |
| MACD | -0.00 | 0.05 |
| Stochastic Oscillator | 79.43 | 94.37 |
Price Performance
Historical ComparisonAbout NUW Nuveen AMT-Free Municipal Value Fund
Nuveen AMT-Free Municipal Value Fund is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax by investing in a portfolio of municipal obligations. The fund predominantly invests in long-term municipal bonds, corporate bonds, short-term municipal bonds, and other assets.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.